Related Experiment Videos
[French as 2005-recommendations on the management of arterial hypertension]
1Service de médecine interne et hypertension, CHU Rangueil, 31059 Toulouse.
Insights
Home blood pressure monitoring helps diagnose hypertension and identify specific conditions. Lifestyle changes are crucial, and multiple medications are often needed to reach blood pressure goals.
Area of Science:
- Cardiology and Hypertension Management
- Clinical Guidelines and Practice Recommendations
- Diagnostic Tools in Hypertension
Context:
- Mild to moderate hypertension (140/90 - 179/109 mmHg) requires accurate diagnosis using home BP or ambulatory BP monitoring.
- Evaluation of target organ damage (TOD) and cardiovascular risk (CV risk) are integral to managing hypertensive patients.
- Systematic screening for microalbuminuria and arterial stiffness is not currently recommended for non-diabetic hypertensive patients.
Purpose:
- To provide evidence-based guidelines for the diagnosis and management of hypertension.
- To outline the role of self blood pressure measurements and target organ damage assessment.
- To detail first-line and second-line antihypertensive therapies and blood pressure goals.
Summary:
- Home BP and ambulatory BP measurements are recommended for diagnosing sustained hypertension and identifying white coat or masked hypertension.
- Cardiovascular risk stratification, incorporating risk factors, TOD, and complications, guides therapeutic decisions.
- Lifestyle modifications are advised for all hypertensive patients, with five drug classes recommended for first-line therapy.
- Combination therapy is frequently necessary, with specific combinations recommended for second-line treatment based on CV risk.
- Blood pressure targets include <140/90 mmHg for all patients, <130/80 mmHg for diabetics and those with chronic renal failure, and a proteinuria reduction goal for high-risk individuals.
Impact:
- These guidelines offer a practical tool for daily clinical practice in hypertension management.
- The recommendations aim to improve patient outcomes by optimizing blood pressure control and cardiovascular risk reduction.
- Applicability and evaluation of these guidelines in real-world settings are essential for their effectiveness.
Abstract:
Self blood pressure measurements (home BP) and/or ambulatory BP measurements are recommended in mild to moderate hypertension (140/90 - 179/109 mmHg) in order to confirm sustained hypertension and identify white coat and masked hypertension. The evaluation of target organ damages (TOD) has to be integrated in cardiovascular risk estimate and taken into account in the management of hypertensive patients. Beside echocardiography, there is a place for the screening of microalbuminuria in non diabetic hypertensive patients, but these investigations should not be performed systematically. Arterial stiffness evaluation and carotid intima-media thickness quantification are not yet recommended. Cardiovascular risk (CV risk) estimate plays a pivotal role in the therapeutic decision and strategy. The cardiovascular risk grade is based on [1] the list of cardiovascular risk factors (same list AFSSAPS recommendations on dyslipidemia), [2] the presence or absence of TOD and [3] cardiovascular complications: "low", "medium", and "high" CV risk. Lifestyle modifications are recommended in all hypertensive patients. Five antihypertensive drugs are recommended for first line therapy: beta-blockers, thiazide diuretics, ACEIs, ARA II and CCBs (and fixed low dose combinations with AFSSAPS agreement for first line). In order to initiate the treatment, Evidence-based therapy (according to clinical trials conducted in different clinical situations), certain comorbid conditions (compelling indications), efficacy and side-effects in a previous experience, and the cost are the determinants of the first choice. Most hypertensive patients require more than one agent to achieve target blood pressure and for second line therapy the recommended combinations are: betablockers-diuretics, ACEIs-diuretics, ARAII-diuretics, betablockers-CCBs (DHP), ACEIs-CCBs, ARA II-CCBs and CCBs-diuretics. The delay to establish a combination therapy depend on CV risk. The BP goals are those recommended by ESH-ESC 2003: BP<140/90 mmHg in all, BP<130/80 mmHg in diabetic patients and in patients with chronic renal failure. Beside lowering BP, the reduction in proteinuria <500 mg/24 h is a new goal in these high risk patients. These guidelines provide a tool for every day practice and applicability should be evaluated.
Related Concept Videos
Atherosclerosis III: Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Atherosclerosis IV: Nursing Management
Hypertension V: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Hypertension and Regulation of Blood Pressure